{"id":473676,"date":"2020-03-13T12:56:01","date_gmt":"2020-03-13T12:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=473676"},"modified":"2020-03-13T12:56:01","modified_gmt":"2020-03-13T12:56:01","slug":"complex-regional-pain-syndrome-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/complex-regional-pain-syndrome-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_473676.html","title":{"rendered":"Complex Regional Pain Syndrome Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight"},"content":{"rendered":"
\"Complex<\/a><\/p>\n
\n
“Complex Regional Pain Syndrome (CRPS) – Market Insight, Epidemiology and Market Forecast – 2030”<\/div>\n<\/div>\n<\/div>\n

Albany, US –<\/strong> DelveInsight has launched a new report on Complex Regional Pain Syndrome Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

DelveInsight’s “Complex Regional Pain Syndrome” – Market Insights, Epidemiology & Market Forecast-2030<\/strong>” report provides an overview of the disease and market size of Complex Regional Pain Syndrome (CRPS) for the seven major pharmaceutical markets i.e., the United States, (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This report covers the various treatment practices, and Complex Regional Pain Syndrome (CRPS) forecasted epidemiology from 2020 to 2030, segmented by the seven major markets.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. Among the EU5 countries, Germany<\/strong> had the population of CRPS with 18,459 cases<\/strong>, followed by UK and the France.<\/li>\n
  2. The total cases of Complex Regional Pain Syndrome (CRPS) in the 7MM<\/strong> were found to be 253,603<\/strong> in 2017.<\/li>\n
  3. In 7MM, The United States<\/strong> has the highest population of Complex Regional Pain Syndrome which was found to be 179,441<\/strong> in 2017<\/strong>.<\/li>\n
  4. Among 7MM, the United States accounts for the highest market size of Complex Regional Pain Syndrome in comparison with EU5 and Japan.<\/li>\n<\/ol>\n

     <\/p>\n

    Key benefits of the Report<\/strong><\/p>\n

    1. Complex Regional Pain Syndrome  market report covers a descriptive overview and comprehensive insight of the Complex Regional Pain Syndrome  epidemiology and Complex Regional Pain Syndrome  market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. Complex Regional Pain Syndrome market report provides insights on the current and emerging therapies. <\/p>\n

    3. Complex Regional Pain Syndrome market report offers a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

    4. Complex Regional Pain Syndrome market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Complex Regional Pain Syndrome market.<\/p>\n

    Request for Sample Pages: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/complex-regional-pain-syndrome-market<\/a><\/p>\n

    “As per DelveInsight’s analysts, the overall cases of CRPS in both the genders is subjected to increase in the coming years, although females are more frequently affected by CRPS than males.”<\/em><\/strong><\/p>\n

    \"\"<\/em><\/strong><\/p>\n

     <\/p>\n

    Complex regional pain syndrome (CRPS)<\/strong> is defined as a “painful syndrome, which includes regional pain, sensory changes (e.g. allodynia), abnormalities of temperature, abnormal sudomotor activity, edema and an abnormal skin color that occurs after an initiating noxious event such as trauma etc.” CRPS may develop after major trauma, surgery, or minor injury, and progresses with a variable course that ranges from self-limiting, mild symptomatology to chronic disease. Based on the patterns of CRPS, two subtypes of CRPS has been found. The CRPS-I and CRPS-II, differentiated by the absence or presence of peripheral nerve damage, respectively, is demonstrated by electrodiagnostic or physical evidence.<\/p>\n

    The recent FDA declaration of CRPS as an official disease has been a catalyst for new drug development. Various organizations such as National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) are funding effective research of CRPS.<\/p>\n

    Based on the type, CRPS has been categorized into:<\/p>\n